[go: up one dir, main page]

ATE173634T1 - Impfstoff gegen gram-negative bakterielle infektionen - Google Patents

Impfstoff gegen gram-negative bakterielle infektionen

Info

Publication number
ATE173634T1
ATE173634T1 AT95917557T AT95917557T ATE173634T1 AT E173634 T1 ATE173634 T1 AT E173634T1 AT 95917557 T AT95917557 T AT 95917557T AT 95917557 T AT95917557 T AT 95917557T AT E173634 T1 ATE173634 T1 AT E173634T1
Authority
AT
Austria
Prior art keywords
bacterial infections
negative bacterial
gram
vaccine
lps
Prior art date
Application number
AT95917557T
Other languages
English (en)
Inventor
Apurba Bhattacharjee
Alan Cross
Erald Sadoff
Wendell Zollinger
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE173634T1 publication Critical patent/ATE173634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95917557T 1994-04-20 1995-04-20 Impfstoff gegen gram-negative bakterielle infektionen ATE173634T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23040294A 1994-04-20 1994-04-20

Publications (1)

Publication Number Publication Date
ATE173634T1 true ATE173634T1 (de) 1998-12-15

Family

ID=22865082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95917557T ATE173634T1 (de) 1994-04-20 1995-04-20 Impfstoff gegen gram-negative bakterielle infektionen

Country Status (9)

Country Link
US (3) US7025963B1 (de)
EP (1) EP0710118B1 (de)
AT (1) ATE173634T1 (de)
AU (1) AU2356095A (de)
DE (1) DE69506212T2 (de)
DK (1) DK0710118T3 (de)
ES (1) ES2128055T3 (de)
GR (1) GR3029477T3 (de)
WO (1) WO1995029662A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011440A4 (de) * 1997-05-16 2003-08-06 Medical Defense Tech Llc Impfstoff gegen den kern von lipopolysacchariden
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261348A3 (de) 1998-05-01 2012-01-25 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 組合わせの髄膜炎菌ｂ／ｃワクチン
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
JP2004508801A (ja) * 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
US8273360B2 (en) * 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9616116B2 (en) * 2005-10-24 2017-04-11 University Of Maryland, Baltimore Detoxified endotoxin immunogenic compositions and uses thereof
WO2007050606A2 (en) * 2005-10-24 2007-05-03 The University Of Maryland, Baltimore Detoxified endotoxin vaccine and adjuvant and uses thereof
WO2010027499A2 (en) * 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
US8258705B2 (en) * 2009-04-29 2012-09-04 Hubbell Incorporated Scotopically enhanced emergency light and control thereof
AU2010306920A1 (en) 2009-10-12 2012-05-31 New Health Sciences, Inc. Oxygen depletion devices and methods for removing oxygen from red blood cells
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
BR112012008683B8 (pt) 2009-10-12 2022-11-08 Hemanext Inc dispositivo de armazenagem de sangue para armazenar sangue depletado de oxigênio e dióxido de carbono, dispositivo de depleção de oxigênio e dióxido de carbono, método para remover oxigênio e dióxido de carbono de hemácias, sistema de armazenagem de sangue, dispositivo de armazenagem de sangue, método para remover oxigênio de hemácias e método para aumentar os níveis de adenosina trifosfato (atp) nas hemácias
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
EP4091645A1 (de) 2010-08-25 2022-11-23 Hemanext Inc. Verfahren zur erhöhung der qualität von erythrozyten und zur verlängerung ihrer lebensdauer während der lagerung
EP2613805B1 (de) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Nada und/oder nhba überexprimierende meningococcus und davon abgeleiteten aussenmembranvesikeln
JP5859558B2 (ja) 2010-11-05 2016-02-10 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 赤血球の照射及び嫌気性保存
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
ES2923571T3 (es) 2011-08-10 2022-09-28 Hemanext Inc Dispositivo integrado de filtrado de leucocitos, oxígeno y/o CO2 y separación de plasma
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
JP2016517395A (ja) 2013-02-28 2016-06-16 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 血液処理のためのガス枯渇化およびガス添加デバイス
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
WO2016145210A1 (en) 2015-03-10 2016-09-15 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
KR20240067253A (ko) 2015-04-23 2024-05-16 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
KR102675532B1 (ko) 2015-05-18 2024-06-13 헤마넥스트 인코포레이티드 전혈의 저장 방법, 및 그것의 조성물
KR102701687B1 (ko) 2016-05-27 2024-08-30 헤마넥스트 인코포레이티드 혐기성 혈액 저장 및 병원체 불활성화 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB109688A (en) 1916-11-04 1917-09-27 Herbert Senior Vincent Improvements in Steam Jacketed Heating or Boiling Pans and like Receptacles.
EP0109688A3 (de) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Komplexe, Verfahren zu deren Herstellung und diese Komplexe enthaltende Zusammensetzungen
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
EP0367757B1 (de) * 1986-05-23 1994-11-02 SANOFI ANIMAL HEALTH, Inc. GEMEINSAME IMPFUNG UNTER VERWENDUNG EINER PRAPARATION GRAM-NEGATIVER BAKTERIEN OHNE O-SPEZIFISCHEN KOHlEHYDRATSEITENKETTEN
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock

Also Published As

Publication number Publication date
DE69506212T2 (de) 1999-08-05
GR3029477T3 (en) 1999-05-28
US7018636B1 (en) 2006-03-28
WO1995029662A3 (en) 1995-11-30
WO1995029662A2 (en) 1995-11-09
DE69506212D1 (de) 1999-01-07
AU2356095A (en) 1995-11-29
EP0710118B1 (de) 1998-11-25
US20060159702A1 (en) 2006-07-20
EP0710118A1 (de) 1996-05-08
ES2128055T3 (es) 1999-05-01
DK0710118T3 (da) 1999-08-09
US7235644B2 (en) 2007-06-26
US7025963B1 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
DE69506212D1 (de) Impfstoff gegen gram-negative bakterielle infektionen
ATE317013T1 (de) Antigen omp26 aus haemophilus influenzae
Doring et al. Virulence factors of Pseudomonas aeruginosa
Cochrane et al. Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection
EA200100565A1 (ru) Новые стрептококковые антигены
EA200400448A1 (ru) Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
EP1757697A3 (de) Gruppe B-Streptococcus Antigene
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
CA2022420A1 (en) Escherichia coli vaccine
ATE75752T1 (de) Antibiotikum.
EP0869801A4 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
Williams et al. Protein antigens of Staphylococcus epidermidis grown under iron-restricted conditions in human peritoneal dialysate
DE69841331D1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
Ala'Aldeen et al. Immunogenicity and cross-reactivity of the 70-Kda iron-regulated protein of Neisseria meningitidis in man and animals
DK0776214T3 (da) Antibakterialt præparat indeholdende multimert alfa-lactalbumin
BR9407144A (pt) Processo para a expressão de alto nível da proteina de membrana externa P2 de haemophilus influenzae tipo B (HIB-P2) em E.coli; processo de purifição da proteina de membrana externa P2 ou proteina de fusão da mesma;processo de reduplicação da proteina de membrana externa P2 ou proteina de fusão obtida; proteina de membrana externa P2 reduplicada, substancialmente pura, a partir de haemophilus influenzae tipo B (HIB-P2) ou proteina de fusão da mesma; vacina compreendendo a proteina de membrana externa P2 de hamophilus influenzae tipo B (HIB-P2) ou uma proteina de fusão da mesma; processo para obter uma proteina P2 ou conjugado proteina de fusão P2-polissacarídeo; processo para evitar a meningite bacteriana em um animal; vetor pNV-3; vetor pNV-2, e vetor pNV-6
Iovane et al. Effect of Pasteurella haemolytica outer membrane proteins on bovine neutrophils
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
Lång et al. The maltose-inducible 43 kDa major outer membrane protein in Vibrio cholerae is immunogenic and common to different isolates
RU95120818A (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
CY1107670T1 (el) Ανοσοποιηση γαλακτοπαραγωγων αγελαδων με πρωτεϊνη mig
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
Ludovici et al. Column chromatography and cell culture assay of Pseudomonas aeruginosa toxin Z preparations
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee